For millions of people, managing high cholesterol means taking medication every day.
Doctors often prescribe statins or other cholesterol-lowering treatments to help reduce the risk of heart attacks and strokes.
These medications have saved countless lives, but they depend on one important factor: patients must continue taking them regularly.
Unfortunately, this does not always happen. Studies show that many people stop taking cholesterol medications within a year of starting treatment.
Some experience side effects, while others simply find it difficult to maintain a lifelong treatment routine.
Researchers have long wondered whether there could be a more permanent solution. Instead of treating high cholesterol continuously, could doctors make a one-time change that provides lasting protection?
A new clinical trial suggests that this goal may be closer than ever before.
Scientists working with University College London, University College London Hospitals NHS Foundation Trust, and Barts Health NHS Trust have reported encouraging results from an experimental gene-editing therapy called VERVE-102.
Their findings were published in the New England Journal of Medicine.
The treatment focuses on a protein called PCSK9. This protein influences how effectively the liver removes LDL cholesterol from the bloodstream. LDL cholesterol is often called “bad” cholesterol because high levels contribute to the development of clogged arteries, heart attacks, and strokes.
Interestingly, some people are born with genetic changes that naturally reduce PCSK9 activity. These individuals often have very low cholesterol levels and significantly lower rates of cardiovascular disease throughout life. Scientists hoped they could mimic this natural protection using modern gene-editing technology.
VERVE-102 was designed to do exactly that. The therapy is delivered through a single intravenous infusion. Once inside the body, it edits the gene responsible for producing PCSK9, reducing the liver’s ability to make the protein. This allows the liver to remove more LDL cholesterol from circulation.
The first human trial enrolled 35 adults who faced particularly high cardiovascular risks. Some participants had heterozygous familial hypercholesterolemia, an inherited disorder that causes extremely high cholesterol levels. Others had developed coronary artery disease unusually early in life.
Because this was an early-stage study, the primary goal was to determine whether the treatment appeared safe. Researchers also monitored cholesterol levels to see whether the gene edit produced the desired effect.
The results exceeded expectations. Participants receiving the highest dose experienced LDL cholesterol reductions of up to 62 percent. These reductions are comparable to some of the most effective cholesterol-lowering medications currently available.
Even more importantly, the effect appeared durable. Participants who were followed for as long as 18 months continued to show substantial reductions in cholesterol levels, suggesting that the gene edit remained active long after the infusion.
Safety findings were also reassuring. No serious side effects related to the highest dose were reported. Some participants experienced mild infusion reactions or temporary changes in liver tests, but no major safety concerns emerged during the study period.
The findings have generated excitement because they point toward a fundamentally different approach to cardiovascular prevention. Rather than asking patients to remember medication every day, doctors may eventually be able to provide long-lasting protection through a single treatment.
Such an approach could be especially valuable for people with inherited forms of high cholesterol, who often face elevated cardiovascular risks from an early age. It could also help patients who struggle with medication adherence or who cannot tolerate existing treatments.
However, several important questions remain unanswered. Researchers still need to determine how long the cholesterol reductions will last.
Larger studies are also needed to evaluate whether the therapy directly reduces the occurrence of heart attacks, strokes, and cardiovascular deaths. In addition, because gene editing creates permanent changes, long-term safety monitoring will be essential.
When reviewing the study, the strongest aspect is that it successfully demonstrates the potential of gene editing to treat a common chronic disease rather than a rare genetic disorder. The magnitude of cholesterol reduction and the favorable safety profile make the findings particularly noteworthy.
However, the small number of participants means caution is still warranted. While the results are exciting, larger trials must confirm the effectiveness and safety of the treatment before it becomes widely available.
Even so, the study represents an important step toward a future where some chronic diseases may be managed with a single treatment rather than lifelong medication.
If you care about heart health, please read studies about top foods to love for a stronger heart, and why oranges may help fight obesity, diabetes, and heart disease.
For more health information, please see recent studies about simple guide to a 7-day diabetes meal plan, and why you should add black beans to your plate.
